A reported series of pancreatic cancer findings outlines progress on novel therapeutic approaches aimed at improving survival in a disease with low overall prognosis. The dataset describes atebimetinib in a Phase 2a setting combined with chemotherapy, reporting 94% six-month survival in 34 patients. It also highlights Phase 3 results for daraxonrasib, describing an average survival extension of more than 13 months versus 6.7 months with another chemotherapeutic comparator. While these figures are presented as reported trial outcomes rather than independent summaries, they frame continued momentum toward targeted regimens and better sequencing strategies. For clinical development and trial design teams, the key point is that survival endpoints—rather than tumor shrinkage alone—are becoming central to how new pancreatic therapies are positioned, given the field’s history of late-stage resistance and limited durability.